GSK’s Strategy in Emerging Markets: Scale, Diversification and Access
This article was originally published in The Pink Sheet Daily
Executive Summary
Emerging markets present great opportunities, tempered by volatility, vastly different local environments, and ever-changing regulations.
You may also be interested in...
GlaxoSmithKline Steers Away from 'White Pills in Western Markets'
CEO Andrew Witty underlines the company's continued diversification into vaccines, consumer health and emerging markets
GlaxoSmithKline Steers Away from 'White Pills in Western Markets'
CEO Andrew Witty underlines the company's continued diversification into vaccines, consumer health and emerging markets
GSK/Aspen Deal Indicates Rising Interest In Emerging Markets Beyond ‘BRIC’
Aspen gains eight specialist medicines and German manufacturing facility from GlaxoSmithKline: